Pear Therapeutics (Pear Therapeutics) ROCE % : -198.93% (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Pear Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pear Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2022 was -198.93%.

Pear Therapeutics ROCE % Historical Data

The historical data trend for Pear Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pear Therapeutics ROCE % Chart

Pear Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

ROCE %

-34.13

-83.19

-87.46

-126.07

Pear Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
ROCE %	Get a 7-Day Free Trial							-143.99	-100.81	-118.66	-127.46	-198.93

Pear Therapeutics ROCE % Calculation

Pear Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-123.35	/	( ( (197.16 - 47.166)	+	(95.129 - 49.442) )	/ 2 )
	=	-123.35	/	( (149.994	+	45.687)	/ 2 )
	=	-123.35	/	97.8405
	=	-126.07 %

Pear Therapeutics's ROCE % of for the quarter that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	-116.64	/	( ( (119.735 - 48.155)	+	(95.129 - 49.442) )	/ 2 )
	=	-116.64	/	( ( 71.58	+	45.687 )	/ 2 )
	=	-116.64	/	58.6335
	=	-198.93 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

Pear Therapeutics (OTCPK:PEARQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pear Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Pear Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pear Therapeutics (Pear Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pear Therapeutics Inc (OTCPK:PEARQ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 State Street, 13th Floor, Boston, MA, USA, 02109

Website

https://www.peartherapeutics.com

Pear Therapeutics Inc is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDTs), which use software to treat diseases directly. The company's vision is to advance healthcare through the widespread use of PDTs and to be the one-stop shop for PDTs offered by Pear and other organizations that may choose to make their products available to patients, providers, and payors via its commercial platform, known as PearConnect. It features four distinct system components, consisting of PDTs for patient use, the PearMD Clinician Dashboard, an end-to-end patient service center, and a data analytics system configured to aggregate patient engagement, adherence, and clinical outcome data.

Executives

5am Partners Iv, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Erin K. Brenner	officer: Chief Product Dev. Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Julia Strandberg	officer: Chief Commercial Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ronan O'brien	officer: General Counsel & Secretary	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Mccann Corey	director, officer: President and CEO	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Yuri Maricich	officer: Chief Medical Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ellen Snow	officer: Chief Accounting Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Christopherd T Guiffre	officer: CFO, COO, Treas., & Asst. Sec.	65 HAYDEN AVE, LEXINGTON MA 02421
Katherine Jeffery	officer: Chief People Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Paul Mango	director	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Timothy A Wicks	director	C/O PRECISION CASTPARTS CORP., 4650 SW MACADAM AVENUE, SUITE 400, PORTLAND OR 97239
Shivakumar Rajaraman	director	6260 LOOKOUT ROAD, BOULDER CO 80301
Klp Spac 1 Llc	10 percent owner	195 CHURCH STREET , 15TH FLOOR, NEW HAVEN CT 06510
Zack Lynch	director	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Elbrus Investments Pte. Ltd.	10 percent owner	60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891